Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus glargine in type 2 diabetes patients with malignant tumors during glucocorticoid-treated chemotherapy
ChiCTR2100049169Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Sep 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of liraglutide and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: glucose, total cholesterol and 8 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
liraglutideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100049169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049169.